EE04120B1 - Viirusevastase bensimidasoolühendi kristallilisedvormid - Google Patents

Viirusevastase bensimidasoolühendi kristallilisedvormid

Info

Publication number
EE04120B1
EE04120B1 EEP200000584A EEP200000584A EE04120B1 EE 04120 B1 EE04120 B1 EE 04120B1 EE P200000584 A EEP200000584 A EE P200000584A EE P200000584 A EEP200000584 A EE P200000584A EE 04120 B1 EE04120 B1 EE 04120B1
Authority
EE
Estonia
Prior art keywords
crystalline forms
benzimidazole compound
antiviral
antiviral benzimidazole
compound
Prior art date
Application number
EEP200000584A
Other languages
English (en)
Estonian (et)
Inventor
Howard Carter Barry
Neal Glover Bobby
Huang Lian-Feng
William Lancaster Robert
Todd Long Stacey
Catherine Rizzolio Michele
Allen Schmitt Eric
Riddle Sickles Barry
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000584A publication Critical patent/EE200000584A/xx
Publication of EE04120B1 publication Critical patent/EE04120B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200000584A 1998-04-07 1999-04-01 Viirusevastase bensimidasoolühendi kristallilisedvormid EE04120B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807354.7A GB9807354D0 (en) 1998-04-07 1998-04-07 Antiviral compound
PCT/EP1999/002214 WO1999051618A1 (en) 1998-04-07 1999-04-01 Novel crystalline forms of an antiviral benzimidazole compound

Publications (2)

Publication Number Publication Date
EE200000584A EE200000584A (et) 2002-04-15
EE04120B1 true EE04120B1 (et) 2003-08-15

Family

ID=10829932

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000584A EE04120B1 (et) 1998-04-07 1999-04-01 Viirusevastase bensimidasoolühendi kristallilisedvormid

Country Status (28)

Country Link
US (9) US6469160B1 (de)
EP (1) EP1071693B1 (de)
JP (1) JP2002510703A (de)
KR (1) KR20010074472A (de)
CN (1) CN1303390A (de)
AP (1) AP2000001947A0 (de)
AT (1) ATE261452T1 (de)
AU (1) AU752877B2 (de)
BR (1) BR9909474A (de)
CA (1) CA2327494C (de)
DE (1) DE69915461T2 (de)
EA (1) EA002970B1 (de)
EE (1) EE04120B1 (de)
ES (1) ES2216503T3 (de)
GB (1) GB9807354D0 (de)
HR (1) HRP20000669A2 (de)
HU (1) HUP0101669A3 (de)
ID (1) ID27109A (de)
IL (1) IL138697A0 (de)
IS (1) IS5640A (de)
NO (1) NO20005005L (de)
NZ (1) NZ507173A (de)
PL (1) PL343397A1 (de)
SK (1) SK14832000A3 (de)
TR (1) TR200002860T2 (de)
WO (1) WO1999051618A1 (de)
YU (1) YU60900A (de)
ZA (1) ZA200005153B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB0008939D0 (en) * 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
BRPI0311176B8 (pt) 2002-05-16 2021-05-25 Janssen Sciences Ireland Uc pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica
WO2005118586A1 (en) * 2004-06-02 2005-12-15 Sandoz Ag Meropenem intermediate in crystalline form
WO2007004230A2 (en) * 2005-07-05 2007-01-11 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
BRPI0616040A2 (pt) * 2005-09-21 2011-06-07 Nycomed Gmbh cloridrato de sulfonilpirról como inibidor de histona desacetilases
EP2404911A1 (de) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Neue Verfahren zur Herstellung von Piperazinyl- und Diazapanylbenzamidderivate
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CA2667345C (en) * 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR101043794B1 (ko) * 2009-04-13 2011-06-27 청우산업 주식회사 황토판재로 제공되는 기능성 황토방
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
US8546344B2 (en) 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
EP2760859A1 (de) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Kristalline formen von azilsartan, ihre herstellung und verwendung
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
PL4475844T3 (pl) * 2022-10-12 2025-11-12 Takeda Pharmaceutical Company Limited Sposób otrzymywania maribawiru

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399987A (en) * 1965-08-02 1968-09-03 United States Borax Chem 2-alkylaminobenzimidazoles as herbicides
CH443777A (de) * 1965-08-06 1968-02-15 Agripat Sa Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens
US3655901A (en) * 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
WO1994008456A1 (en) * 1992-10-21 1994-04-28 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound

Also Published As

Publication number Publication date
SK14832000A3 (sk) 2001-07-10
ATE261452T1 (de) 2004-03-15
EP1071693B1 (de) 2004-03-10
GB9807354D0 (en) 1998-06-03
US20020177703A1 (en) 2002-11-28
US9163052B2 (en) 2015-10-20
NO20005005L (no) 2000-12-06
EA002970B1 (ru) 2002-12-26
IS5640A (is) 2000-09-26
ES2216503T3 (es) 2004-10-16
US7297683B2 (en) 2007-11-20
US6469160B1 (en) 2002-10-22
ID27109A (id) 2001-03-01
US20130261294A1 (en) 2013-10-03
CN1303390A (zh) 2001-07-11
TR200002860T2 (tr) 2000-12-21
EE200000584A (et) 2002-04-15
US20080103186A1 (en) 2008-05-01
EA200000911A1 (ru) 2001-04-23
HUP0101669A2 (hu) 2001-10-28
US20100179101A1 (en) 2010-07-15
NZ507173A (en) 2003-07-25
US20180044366A1 (en) 2018-02-15
NO20005005D0 (no) 2000-10-04
ZA200005153B (en) 2001-09-26
DE69915461T2 (de) 2005-03-03
US7714123B2 (en) 2010-05-11
CA2327494A1 (en) 1999-10-14
DE69915461D1 (de) 2004-04-15
HRP20000669A2 (en) 2001-08-31
KR20010074472A (ko) 2001-08-04
PL343397A1 (en) 2001-08-13
US20170002035A1 (en) 2017-01-05
EP1071693A1 (de) 2001-01-31
HUP0101669A3 (en) 2003-07-28
US20160030460A1 (en) 2016-02-04
IL138697A0 (en) 2001-10-31
JP2002510703A (ja) 2002-04-09
AU3603499A (en) 1999-10-25
WO1999051618A1 (en) 1999-10-14
AU752877B2 (en) 2002-10-03
AP2000001947A0 (en) 2000-12-31
YU60900A (sh) 2003-07-07
CA2327494C (en) 2010-10-26
BR9909474A (pt) 2000-12-19
US20110118203A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
EE200000584A (et) Viirusevastase bensimidasoolühendi kristallilisedvormid
LTPA2009006I1 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
NO20015536D0 (no) FAP-aktiverte anti-tumor-forbindelser
NO20011745L (no) Forbindelser
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
NO20005795D0 (no) Antivirale forbindelser
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
DE50009640D1 (de) Drehmaschine
NO20005006D0 (no) Kalsilytiske forbindelser
NO20013684D0 (no) Substituerte fenetylaminderivater
ID30516A (id) Senyawa-senyawa (aminoiminometil atau aminometil) benzoheteroaril tersubstitusi
NO20006662L (no) Fluorfenylresin-forbindelser
DK1054867T3 (da) Antivirale midler
IS5821A (is) Kristalluð form af ósanetant
FI982378A0 (fi) Järjestely kohteen tutkimiseen
PT1175417E (pt) Compostos substituidos de benzolactamas
IT250476Y1 (it) Struttura di elemento di aggancio particolarmente per la connessionereciproca di due parti
ITMI982758A1 (it) Procedimento per la purificazione di 7-glutaril aca
HK1032973A (en) Novel crystalline forms of an antiviral benzimidazole compound
IT1302547B1 (it) Struttura multistrato per la realizzazione di elementi diprotezione
IDP000021790A (id) Senyawa-senyawa pirolum tersubstitusi
IDP000021799A (id) Senyawa-senyawa pirolum tersubstitusi
SE9904417D0 (sv) Crystalline form

Legal Events

Date Code Title Description
HD1A Correction of address
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20050401